Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Walkty

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
The Journal of Antimicrobial Chemotherapy|August 11, 2021
Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007-18Alyssa R Golden, James A Karlowsky, Andrew Walkty, et al.
Diagnostic Microbiology and Infectious Disease|June 3, 2008
Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006George G Zhanel, Mel DeCorby, Kim A Nichol, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2025
Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007-23)Laura F Mataseje, Nicole Lerminiaux, Philippe Lagacé-Wiens, et al.
Expert Review of Anti-Infective Therapy|April 20, 2012
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacinGeorge G Zhanel, Christopher D Lawson, Sheryl Zelenitsky, et al.
Drugs|February 11, 2016
Review of Eravacycline, a Novel Fluorocycline Antibacterial AgentGeorge G Zhanel, Doris Cheung, Heather Adam, et al.
Jac-Antimicrobial Resistance|February 14, 2022
Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007-19Alyssa R Golden, Melanie R Baxter, James A Karlowsky, et al.
Expert Review of Anti-Infective Therapy|September 26, 2024
Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registryGeorge G Zhanel, Rita Dhami, Melanie Baxter, et al.
The Journal of Antimicrobial Chemotherapy|April 17, 2013
Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 studyGeorge G Zhanel, Heather J Adam, Melanie R Baxter, et al.
Journal of Global Antimicrobial Resistance|June 22, 2024
Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registryGeorge Zhanel, Michael Silverman, Janhavi Malhotra, et al.
Journal of Global Antimicrobial Resistance|February 4, 2021
Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registryGeorge G Zhanel, Justin Kosar, Melanie Baxter, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
The Journal of Antimicrobial Chemotherapy|August 11, 2021
Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007-18Alyssa R Golden, James A Karlowsky, Andrew Walkty, et al.
Diagnostic Microbiology and Infectious Disease|June 3, 2008
Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006George G Zhanel, Mel DeCorby, Kim A Nichol, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2025
Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007-23)Laura F Mataseje, Nicole Lerminiaux, Philippe Lagacé-Wiens, et al.
Expert Review of Anti-Infective Therapy|April 20, 2012
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacinGeorge G Zhanel, Christopher D Lawson, Sheryl Zelenitsky, et al.
Drugs|February 11, 2016
Review of Eravacycline, a Novel Fluorocycline Antibacterial AgentGeorge G Zhanel, Doris Cheung, Heather Adam, et al.
Jac-Antimicrobial Resistance|February 14, 2022
Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007-19Alyssa R Golden, Melanie R Baxter, James A Karlowsky, et al.
Expert Review of Anti-Infective Therapy|September 26, 2024
Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registryGeorge G Zhanel, Rita Dhami, Melanie Baxter, et al.
The Journal of Antimicrobial Chemotherapy|April 17, 2013
Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 studyGeorge G Zhanel, Heather J Adam, Melanie R Baxter, et al.
Journal of Global Antimicrobial Resistance|June 22, 2024
Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registryGeorge Zhanel, Michael Silverman, Janhavi Malhotra, et al.
Journal of Global Antimicrobial Resistance|February 4, 2021
Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registryGeorge G Zhanel, Justin Kosar, Melanie Baxter, et al.
Pageof 11